

# Amoeba

## Preparing for commercialisation in 2026

FY25 results

Amoéba's FY25 was marked by regulatory and pre-commercial progress across biocontrol and cosmetics, alongside higher industrial deployment spend ahead of a planned move into commercialisation in 2026. Operating loss declined to €6.8m (FY24: loss of €5.7m), mainly due to higher deployment costs as production capacity increased (notably at Chassieu), while R&D and G&A were marginally lower year-on-year. Commercially, Amoéba advanced a partner-led route to market via a distribution agreement with Koppert (18 European countries and the US) and a memorandum of understanding (MoU) with Syngenta (cereals and field crops in Europe and the UK). Liquidity improved following the July 2025 capital increase and additional bond tranches, with Nice & Green confirming continued financial support to at least end-2026. We will update our forecasts and valuation once more information is available.

Year end	Revenue (€m)	EBIT (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)
12/24	0.6	(5.7)	(6.6)	(0.13)	0.00	N/A
12/25e	0.0	(6.4)	(7.3)	(0.11)	0.00	N/A
12/26e	3.4	(4.3)	(4.8)	(0.07)	0.00	N/A
12/27e	13.5	2.6	1.6	0.02	0.00	49.6

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Grants increased to €0.7m (FY24: €0.6m), but the P&L saw higher industrial deployment spend ahead of commercialisation. Deployment costs rose to €2.6m (FY24: €1.5m) as Amoéba increased production capacity, particularly at Chassieu. The rest of the cost base was broadly stable: R&D was €1.6m and administrative costs/overheads were €2.7m, both in line with FY24, while sales and marketing expenses increased to €0.6m (FY24: €0.4m) as launch preparation activity stepped up. The net loss widened to €8.3m (FY24: €6.6m), with financial expenses rising to €1.5m (FY24: €0.9m), linked to the bond loan in 2025.

Amoéba framed FY25 as a shift from R&D to pre-commercial biocontrol execution, supported by its regulatory position and a partner-led go-to-market strategy. It reiterated that its active substance is approved in Europe and AXPERA has marketing authorisation in the US, and noted (post year-end) that ANSES (the French regulator) has initiated the final evaluation phase for AXPERA marketing authorisation in France. Commercially, the group is relying on third parties to reach end markets, with Koppert distributing into 18 European countries and the US (and launching TIAGAN, intended to replace AXPERA for viticultural uses) and an MoU with Syngenta covering cereals and field crops in Europe and the UK. In cosmetics, Amoéba signed an agreement with Oriental Beauty Valley Group in China, in July 2025, and notes its cosmetic ingredient is listed on the INCI list, enabling worldwide commercialisation except in China, where local approval is required.

Liquidity improved in FY25, with year-end cash of €4.7m (FY24: €0.5m) following the July 2025 capital increase. Cash outflows remained significant (operating costs €6.1m and investments €1.3m), but were more than covered by €11.7m of financing inflows, mainly the €8.0m cash capital increase and €4.0m from new tranches under the non-convertible bond loan. Equity remained negative at €5.4m (FY24: negative €10.4m) and financial debt was €12.2m (FY24: €12.1m), largely the Nice & Green simple bond loan (€11.4m at end-FY25). Nice & Green confirmed continued financial support to at least 31 December 2026; Amoéba stated this underpins its going concern and extends its cash horizon to end-2026.

### Industrial engineering

19 March 2026

<b>Price</b>	<b>€0.99</b>
<b>Market cap</b>	<b>€71m</b>
Net cash/(debt) at 31 December 2024	€(11.1)m
Shares in issue	68.9m
Free float	47.6%
Code	ALMIB
Primary exchange	NXT PA
Secondary exchange	N/A

### Share price performance



### Business description

Amoéba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops. These novel fungicides are based on the characteristics of the *Willaertia magna* C2c Maky amoeba.

### Analysts

Harry Kilby	+44 (0)20 3077 5700
Finlay Mathers	+44 (0)20 3077 5700

[industrials@edisongroup.com](mailto:industrials@edisongroup.com)  
[Edison profile page](#)

**Amoeba is a research client of  
 Edison Investment Research  
 Limited**

---

## General disclaimer and copyright

This report has been commissioned by Amoeba and prepared and issued by Edison, in consideration of a fee payable by Amoeba. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.